Safety of Pyrazinamide for the Treatment of Tuberculosis in Older Patients Over 75 Years of Age: A Retrospective Monocentric Cohort Study.
Journal
Drugs & aging
ISSN: 1179-1969
Titre abrégé: Drugs Aging
Pays: New Zealand
ID NLM: 9102074
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
accepted:
17
10
2020
pubmed:
5
11
2020
medline:
25
2
2023
entrez:
4
11
2020
Statut:
ppublish
Résumé
Pyrazinamide (PZA) has a controversial safety profile in older patients. We aimed to assess the frequency and risk factors for adverse drug reactions (ADRs) in patients over 75 years of age treated for tuberculosis with or without PZA. We conducted a retrospective monocentric study including patients aged over 75 years treated for active tuberculosis between 2008 and 2018. The frequency, type, seriousness, and causality assessment of ADRs to anti-tuberculosis treatment were compared between patients receiving PZA or not. Risk factors for ADRs were investigated using univariable and multivariable analyses by logistic regression. Among the 110 patients included, 54 (49.1%) received PZA (group 1) and 56 (50.9%) did not (group 2). ADRs to anti-tuberculosis drugs occurred in 31 patients (57.4%) in groups 1 and 15 (26.8%) in group 2 (p = 0.003). PZA-related ADRs occurred in 40.7% of exposed patients. Frequency of renal ADRs was higher in group 1 (9.3% vs 0%; p = 0.026). Rates of hepatic (18.5% vs 12.5%; p = 0.38), digestive (22.2% vs 8.9%; p = 0.054), and allergic (14.8% vs 5.4%; p = 0.12) ADRs were numerically higher in group 1 although the differences were not statistically significant. Serious ADRs occurred more frequently in group 1 (24.1% vs 8.9%; p = 0.03). The use of PZA was the only independent risk factor for ADRs to anti-tuberculosis drugs (odds ratio 3.75, 95% CI 1.5-9.6; p = 0.0056). No risk factors for PZA-related ADRs were identified. In older French patients, the use of PZA was associated with more frequent ADRs to anti-tuberculosis drugs.
Identifiants
pubmed: 33145702
doi: 10.1007/s40266-020-00811-9
pii: 10.1007/s40266-020-00811-9
doi:
Substances chimiques
Antitubercular Agents
0
Pyrazinamide
2KNI5N06TI
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
43-52Références
Framework towards Tuberculosis Elimination in Low-Incidence Countries. Geneva: World Health Organization; 2014.
Davies PD. Tuberculosis in the elderly. Epidemiology and optimal management. Drugs Aging. 1996;8:436–44. https://doi.org/10.2165/00002512-199608060-00005 .
doi: 10.2165/00002512-199608060-00005
pubmed: 8736627
Rajagopalan S. Tuberculosis and aging: a global health problem. Clin Infect Dis Off Publ Infect Dis Soc Am. 2001;33:1034–9. https://doi.org/10.1086/322671 .
doi: 10.1086/322671
Santé Publique France. Tuberculose. 2020. https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/tuberculose/donnees/#tabs . Accessed 24 Jan 2020.
Yen Y-F, Feng J-Y, Pan S-W, Chuang P-H, Su VY-F, Su W-J. Determinants of mortality in elderly patients with tuberculosis: a population-based follow-up study. Epidemiol Infect. 2017;145:1374–81. https://doi.org/10.1017/S0950268817000152 .
Zhang Y, Shi W, Zhang W, Mitchison D. Mechanisms of pyrazinamide action and resistance. Microbiol Spectr. 2014. https://doi.org/10.1128/microbiolspec.MGM2-0023-2013 .
A controlled trial of 6 months’ chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society. Br J Dis Chest. 1984;78:330–6.
Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9:2026–30.
doi: 10.1183/09031936.96.09102026
Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472–7. https://doi.org/10.1164/rccm.200206-626OC .
doi: 10.1164/rccm.200206-626OC
pubmed: 12569078
Di Gennaro F, Vittozzi P, Gualano G, Musso M, Mosti S, Mencarini P, et al. Active pulmonary tuberculosis in elderly patients: a 2016–2019 retrospective analysis from an Italian Referral Hospital. Antibiot Basel Switz. 2020. https://doi.org/10.3390/antibiotics9080489 .
Kwon BS, Kim Y, Lee SH, Lim SY, Lee YJ, Park JS, et al. The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis. PLoS ONE. 2020;15:e0236109. https://doi.org/10.1371/journal.pone.0236109 .
doi: 10.1371/journal.pone.0236109
pubmed: 32692774
pmcid: 7373258
Perriot J, Chambonnet E, Eschalier A. Managing the adverse events of antitubercular agents. Rev Mal Respir. 2011;28:542–55. https://doi.org/10.1016/j.rmr.2010.10.034 .
doi: 10.1016/j.rmr.2010.10.034
pubmed: 21549908
Leung CC, Yew WW, Chan CK, Chau CH, Tam CM, Lam CW, et al. Tuberculosis in older people: a retrospective and comparative study from Hong Kong. J Am Geriatr Soc. 2002;50:1219–26. https://doi.org/10.1046/j.1532-5415.2002.50308.x .
doi: 10.1046/j.1532-5415.2002.50308.x
pubmed: 12133016
Lin H-S, Cheng C-W, Lin M-S, Chou Y-L, Chang P-J, Lin J-C, et al. The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide. Clin Interv Aging. 2016;11:299–306. https://doi.org/10.2147/CIA.S95411 .
doi: 10.2147/CIA.S95411
pubmed: 27042029
pmcid: 4795580
Bright-Thomas RJ, Gondker AR, Morris J, Ormerod LP. Drug-related hepatitis in patients treated with standard anti-tuberculosis chemotherapy over a 30-year period. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2016;20:1621–4. https://doi.org/10.5588/ijtld.16.0370 .
doi: 10.5588/ijtld.16.0370
Kwon YS, Chi SY, Oh IJ, Kim KS, Kim YI, Lim SC, et al. Clinical characteristics and treatment outcomes of tuberculosis in the elderly: a case control study. BMC Infect Dis. 2013;13:121. https://doi.org/10.1186/1471-2334-13-121 .
doi: 10.1186/1471-2334-13-121
pubmed: 23510403
pmcid: 3599150
Miyazawa N, Horita N, Tomaru K, Tsukahara T, Takahashi R, Sasaki M, et al. Comparison of drug-induced hepatitis occurring in elderly and younger patients during anti-tuberculosis treatment with a regimen including pyrazinamide. Kekkaku. 2013;88:297–300.
Horita N, Miyazawa N, Yoshiyama T, Kojima R, Ishigatsubo Y, Kaneko T. Currently used low-dose pyrazinamide does not increase liver-injury in the first two months of tuberculosis treatment. Int Med Tokyo Jpn. 2015;54:2315–20. https://doi.org/10.2169/internalmedicine.54.5533 .
doi: 10.2169/internalmedicine.54.5533
Takaku T, Saito T, Nemoto K, Oisihi S, Hayashihara K. Comparison of adverse effects in tuberculosis patients over 80 years of age with and without pyrazinamide treatment. Eur Respir J. 2017;50:PA3045. https://doi.org/10.1183/1393003.congress-2017.PA3045 .
Hagiwara E, Suido Y, Asaoka M, Katano T, Okuda R, Sekine A, et al. Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: a prospective randomized open-label study. J Infect Chemother Off J Jpn Soc Chemother. 2019. https://doi.org/10.1016/j.jiac.2019.05.030 .
doi: 10.1016/j.jiac.2019.05.030
Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63:e147–95. https://doi.org/10.1093/cid/ciw376 .
doi: 10.1093/cid/ciw376
pubmed: 27516382
pmcid: 6590850
Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992;41:237–48. https://doi.org/10.1016/0165-1781(92)90005-n .
doi: 10.1016/0165-1781(92)90005-n
pubmed: 1594710
Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. the index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914–9. https://doi.org/10.1001/jama.1963.03060120024016 .
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.
doi: 10.1097/00000421-198212000-00014
Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957–63. https://doi.org/10.1001/jama.270.24.2957 .
doi: 10.1001/jama.270.24.2957
pubmed: 8254858
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
MedDRA. 2020. https://www.meddra.org/ . Accessed 28 Jan 2020.
Code de la santé publique—Article R5121-152. vol. R5121-152. 2020.
Bégaud B, Evreux JC, Jouglard J. Lagier G [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Therapie. 1985;40:111–8.
pubmed: 4002188
Huang Y-S. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol. 2007;3:1–8. https://doi.org/10.1517/17425255.3.1.1 .
doi: 10.1517/17425255.3.1.1
pubmed: 17269890
Sanwikarja S, Kauffmann RH, te Velde J, Serlie J. Tubulointerstitial nephritis associated with pyrazinamide. Neth J Med. 1989;34:40–6.
pubmed: 2915734
Namba S, Igari T, Nishiyama K, Hashimoto K, Takemura T, Kimura K. A case of pyrazinamide-associated myoglobinuric renal failure. Jpn J Med. 1991;30:468–72. https://doi.org/10.2169/internalmedicine1962.30.468 .
doi: 10.2169/internalmedicine1962.30.468
pubmed: 1803050
Siddiqui AN, Khayyam KU, Sharma M. Effect of diabetes mellitus on tuberculosis treatment outcome and adverse reactions in patients receiving directly observed treatment strategy in India: a prospective study. BioMed Res Int. 2016;2016:7273935. https://doi.org/10.1155/2016/7273935 .
doi: 10.1155/2016/7273935
pubmed: 27642601
pmcid: 5013229
Riza AL, Pearson F, Ugarte-Gil C, Alisjahbana B, van de Vijver S, Panduru NM, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol. 2014;2:740–53. https://doi.org/10.1016/S2213-8587(14)70110-X .
doi: 10.1016/S2213-8587(14)70110-X
pubmed: 25194887
pmcid: 4852378
Morris CD. Pulmonary tuberculosis in the elderly: a different disease? Thorax. 1990;45:912–3. https://doi.org/10.1136/thx.45.12.912 .
doi: 10.1136/thx.45.12.912
pubmed: 2281421
pmcid: 462835
Pérez-Guzmán C, Vargas MH, Torres-Cruz A, Villarreal-Velarde H. Does aging modify pulmonary tuberculosis?: a meta-analytical review. Chest. 1999;116:961–7. https://doi.org/10.1378/chest.116.4.961 .
doi: 10.1378/chest.116.4.961
pubmed: 10531160
Abbara A, Collin SM, Kon OM, Buell K, Sullivan A, Barrett J, et al. Time to diagnosis of tuberculosis is greater in older patients: a retrospective cohort review. ERJ Open Res. 2019. https://doi.org/10.1183/23120541.00228-2018 .
Wang J-Y, Hsueh P-R, Jan I-S, Lee L-N, Liaw Y-S, Yang P-C, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax. 2006;61:903–8. https://doi.org/10.1136/thx.2005.056887 .
doi: 10.1136/thx.2005.056887
pubmed: 16809417
pmcid: 2104756
Wang J-Y, Lee C-H, Yu M-C, Lee M-C, Lee L-N, Wang J-T. Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study. Eur Respir J. 2015;46:567–70. https://doi.org/10.1183/09031936.00019915 .
doi: 10.1183/09031936.00019915
pubmed: 25900374
Wilkinson RJ, Rohlwink U, Misra UK, van Crevel R, Mai NTH, Dooley KE, et al. Tuberculous meningitis. Nat Rev Neurol. 2017;13:581–98. https://doi.org/10.1038/nrneurol.2017.120 .
doi: 10.1038/nrneurol.2017.120
pubmed: 28884751
WHOcausality_assessment.pdf. 2020. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf . Accessed 28 Jan 2020.